On May 5, 2026, Mondaq, a U.S.-based legal content aggregation platform, officially announced the winners of its Spring 2026 Thought Leadership Awards (https://awards.mondaq.com/Home/Topics/16/11). Recognized for his outstanding professional performance in the field of Food, Drugs, Healthcare, and Life Sciences, Aaron Gu of Han Kun Law Offices has once again received the award following his 2023 and 2025 recognition.
Award-winning Article
Key Takeaways: China's Revised Medical Device GCP
Overview of the Award-Winning Article
As China's medical device regulatory framework continues to mature and upgrade, the implementation of the revised Good Clinical Practice for Medical Devices (GCP) marks a new era of higher standards and increased clarity for the industry. Drawing on deep industry expertise and ongoing regulatory monitoring, the Aaron Gu team breaks down the key highlights of the new Medical Device GCP—including the heightened emphasis on ethical responsibilities, the formal inclusion of IVD into regulatory scope, and the clarification of stakeholders' duties. The article aims to help companies navigate policy shifts and maintain strict compliance while accelerating product R&D and achieving high-quality growth.
About Mondaq
Mondaq is a well-known U.S.-based legal content aggregation platform dedicated to providing global users with in-depth insights and high-quality articles from professional legal service providers worldwide. The Mondaq Thought Leadership Awards are announced twice a year, in Spring and Autumn, to recognize the authors whose articles have achieved the highest cumulative readership across multiple countries and practice areas over the previous six months, highlighting their outstanding influence within the industry.
Aaron Gu's Profile
Mr. Gu specializes in corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, Spin off-NewCo transactions, drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Specifically, Mr. Gu's services cover a full range of products including drugs, medical devices, IVDs, cosmetics, general foods, special foods, animal drugs, animal foods, etc.
Mr. Gu has extensive experience representing various types of companies in the life sciences industry, including renowned multinational pharmaceutical companies, leading Chinese innovative drug and biotechnology companies, and top domestic and international investment institutions. Mr. Gu has co-authored the China section of Chambers Life Sciences Global Practice Guide (2022-2025) and other publications. His outstanding and professional services have earned him numerous accolades from prestigious institutions such as Chambers and Partners, The Legal 500, China Business Law Journal, Lexpress, LegalOne, Lex Falcon Global Awards, Asian Legal Business (ALB), Legalband and Mondaq. Furthermore, Mr. Gu has been interviewed by 36Kr, Blue View, Caixin, China Business Network, Dutch Financial Daily, Economic Observer, Faxian Magazine, Financial Times, Healthcare Executive, International Pharmaceutical News for China, Jiemian, Southern Weekly, Thomson Reuters and other media (in alphabetical order).
